It can be expressed by several tumor types, including breast and gastroesophageal cancers [69], but also by a small proportion of KRAS-BRAF-wild type CRC, where it was identified as a mechanism of resistance for EGFR antibody therapies [70]. This evidence concerns the gene KRAS and neoplasm.